A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma.

Trial Profile

A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Cisplatin (Primary) ; Pemetrexed (Primary) ; Rilotumumab (Primary)
  • Indications Mesothelioma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2011 Amgen has discontinued development of rilotumumab; however, the status of this trial is not clear.
    • 19 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top